Haemophagocytic lymphohistiocytosis: a life threatening complication of lymphoma.
New risk scores and non-toxic anti-inflammatory options help manage the life-threatening inflammation that complicates lymphoma treatment.
This narrative review in Current Opinion in Oncology synthesizes recent evidence on L-HLH, a life-threatening hyperinflammatory complication of lymphoma that requires balancing urgent inflammation control, diagnostic workup, and lymphoma-directed therapy simultaneously. Key updates include the OHI scoring system for MOF risk prediction, new evidence for early lymphoma therapy, and non-myelosuppressive options (anakinra, ruxolitinib, IVIg) for critically ill patients.
What the study was
- Study design
- Narrative review
- Population
- Patients with lymphoma-associated HLH (L-HLH)
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Current Opinion in Oncology
Why it surfaced
Clinically focused update review on a life-threatening lymphoma complication with emerging diagnostic and therapeutic tools; relevant for T1 lymphoma surveillance.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.